Table 2.

Canonical pathways and the gene affected by the trans-resveratrol in presence of Porphyromonus gingivalis lipopolysaccharide (PgLPS) treatment in the IMR-32 neuroblastoma cells

Pathways	Effect	Genes affected within the pathway	Z-score	P-value
Oxidative stress
Production of NO and ROS	Inhibition	AKT1, FOS, IKBKB, IRF1, JAK2, MAP3K1, NFKB1, PIK3R1, RELA, STAT1, TNF, TNFRSF1	− 2.309	1.51E−13
iNOS signaling	Inhibition	FOS, IKBKB, IRAK1, IRAK2, IRF1, JAK2, NFKB1, RELA, STAT1	− 2.330	6.10E−17
Inflammation
NF-kB signaling	Inhibition	AKT1, CD40, EGF, GSK3B, IGF1R, IKBKB, IL1B, INSR, IRAK1, MAP3K1, MYD88, NFKB1, PIK3R1, RELA, TNFA, TNFRSF1A, TRAF2, TRAF5	− 2.089	2.02E−27
Neuroinflammation signaling	Inhibition	AKT1, CD40, CREB1, CSF1R, FOS, GSK3B, IDE, IKBKB, IL6, IL1B, IL6R, IRAK1, IRAK2, JAK2, MYD88, NFKB1, PIK3R1, PTGS2, RELA, SOD2, STAT1, TGFB1	− 2.000	2.70E−32
Acute phase response	Inhibition	AKT1, FOS, IKBKB, IL6, IL1B, IL6R, IRAK1, JAK2, MAP3K1, MYD88, NFKB1, PIK3R1, RELA, SOD2, STAT3, TNF, TNFRSF1A, TRAF2	− 2.186	9.55E−24
IL-6 signaling	Inhibition	AKT1, FOS, IKBKB, IL6, IL1B, IL6R, JAK2, NFKB1, PIK3R1, RELA, STAT3, TNF, TNFRSF1A, TRAF2, VEGFA	− 2.324	3.89E−21
IL-8 signaling	Inhibition	AKT1, EGF, FOS, IKBKB, IRAK1, IRAK2, NFKB1, PIK3R1, PTGS2, RELA, VCAM1, VEGFA	− 2.111	2.75E−13
CD40 signaling	Inhibition	CD40, FOS, IKBKB, NFKB1, PIK3R1, PTGS2, RELA, STAT3, TRAF2, TRAF5	− 2.333	1.61E−15
Metabolism
PTEN signaling	Activation	AKT1, FOXO1, GSK3B, IGF1R, IKBKB, INSR, NFKB1, PIK3R1, RELA	2.121	6.43E−11
PPARa/RXRa activation	Activation	ADIPOQ, IKBKB, IL6, IL1B, INSR, IRS1, JAK2, NFKB1, RELA, TGFB1	2.111	4.61E−12
PPAR signaling	Activation	FOS, IKBKB, IL1B, INSR, NFKB1, PTGS2, RELA, TNF, TNFRSF1A, TRAF2	2.001	4.26E−15
IGF-1 signaling	Inhibition	AKT1, FOS, FOXO1, IGF1, IGF1R, IRS1, JAK2, PIK3R1, STAT3	− 2.121	2.63E−13
Insulin receptor signaling	Inhibition	AKT1, FOXO1, GAB1, GSK3B, INSR, IRS1, JAK2, PIK3R1	− 2.017	1.97E−10